Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074807 | 0.78 | EGFR (0.50) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL559673 | 0.77 | EGFR (0.48) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL276425 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL12747762 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL10765869 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CACYP1A2 | |
| SCHEMBL13857915 | 0.75 | PSMD14 (0.55) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL2008884 | 0.75 | CYP3A4 (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL276426 | 0.75 | METAP2 (0.55) | EGFRTRPV1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2008880 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL7989490 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| CN-107207467-A | 2, 4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | 癌症研究科技有限公司 | 2017-09-26 | — | — | CN | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3006029-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | Kaken Pharmaceutical Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20150166506-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2789607-A1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885TRPV1 1610/4885PIK3CD 168/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885TRPV1 2138/4885PIK3CD 213/4885 |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | EGFR 2302/4885TRPV1 2334/4885PIK3CD 931/4885 |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | EGFR 2445/4885TRPV1 2440/4885PIK3CD 1402/4885 |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | PF4, F2, PFKP | EGFR 3489/4885TRPV1 3575/4885PIK3CD 113/4885 |
| US-20150166506-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | EGFR 2302/4885TRPV1 2334/4885PIK3CD 931/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | EGFR 340/4885TRPV1 4147/4885PIK3CD 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.